Diagnostic performance of MDCT, PET/CT and gadoxetic acid (Primovist®)-enhanced MRI in patients with colorectal liver metastases being considered for hepatic resection: Initial experience in a single centre

Irish Journal of Medical Science

Volumn 181, Issue 4, 2012, Pages 499-509

  Chan, V O ^a   Das, J P ^a   Gerstenmaier, J F ^a   Geoghegan, J ^a   Gibney, R G ^a   Collins, C D ^a,b   Skehan, S J ^a,b   Malone, D E ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b Blackrock Clinic Ireland   (Ireland)

Author keywords

Colorectal liver metastases; Computed tomography; Magnetic resonance imaging; Positron emission tomography; Primovist

Indexed keywords

GADOXETIC ACID;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; COLORECTAL CANCER; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER METASTASIS; LIVER RESECTION; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; COLORECTAL NEOPLASMS; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84867828914     PISSN: 00211265     EISSN: 18634362     Source Type: Journal    
DOI: 10.1007/s11845-012-0805-x     Document Type: Article

References (103)

1. Boyle P, Langman JS (2000) ABC of colorectal cancer: epidemiology. BMJ 321(7264):805-808
2. Bipat S, van Leeuwen MS, Comans EFI et al (2005) Colorectal liver metastases: CT, MR imaging and PET for diagnosismeta-analysis. Radiology 237:123-131
3. Erturk SM, Ichikawa T, Fujii H, Yasuda S, Ros PR (2006) PET imaging for evaluation of metastatic colorectal cancer of the liver. Eur J Radiol 58(2):229-235
4. Schima W, Kulinna C, Langenberger H, Ba-Ssalamah A (2005) Liver metastases of colorectal cancer: US, CT or MR? Cancer Imaging 5:S149-S155
5. Ruers T, Bleichrodt RP (2002) Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer 38(7):1023-1033
6. Simmonds PC, Primrose NJ, Colquitt JL, Garden OJ, Poston GJ, Rees M (2006) Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 94(7):982-999
7. Jatzko GR, Lisborg PH, Stettner HM, Klimpfinger MH (1995) Hepatic resection for metastases from colorectal carcinoma: a survival analysis. Eur J Cancer 31A:41-46
8. Castells A, Bessa X, Daniels M et al (1998) Value of postoperative surveillance after radical surgery for colorectal cancer: results of a cohort study. Dis Colon Rectum 41:714-723
9. Komborozos VA, Skrekas GJ, Pissiotis CA (2001) The contribution of follow-up programs in the reduction of mortality of rectal cancer recurrences. Dig Surg 18:403-408
10. Safi F, Link KH, Beger HG (1993) Is follow-up of colorectal cancer patients worthwhile? Dis Colon Rectum 36:636-643
11. Ketteniss M, Schutz G, Ulrich B (2001) Costs and efficiency of a tumor follow-up program for the detection of colorectal liver metastases. Int J Colorectal Dis 16:28-31
12. Lodge JPA (2000) Modern surgery for liver metastases. Cancer Imaging 1:77-79
13. Rees M, John TG (2001) Current status of surgery in colorectal metastases to the liver. Hepatogastroenterology 48:341-344
14. Scheele J, Stangl R, Altendorf-Hofman A (1990) Hepatic metastases from colorectal cancer: impact of surgical resection on the natural history. Br J Surg 77:1241-1246
15. Stangl R, Altendorf-Hofman A, Charnely R, Scheele J (1994) Factors influencing the natural history of colorectal liver metastases. Lancet 343:1405-1410
16. Simmonds PC (2000) Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 321(7260):531-535
17. Sica GT, Ji H, Ross PR (2000) CT and MR imaging of hepatic metastases. AJR 174:691-698
18. Ong KO, Leen E (2007) Radiological staging of colorectal liver metastases. Surg Oncol 16(1):7-14
19. Scott DJ, Guthrie JA, Arnold P et al (2001) Dual phase helical CT versus portal venous phase CT for the detection of colorectal liver metastases: correlation with intra-operative sonography, surgical and pathological findings. Clin Radiol 56:235-242
20. Kuszyk BS, Bluemke DA, Urban BA et al (1996) Portal-phase contrast-enhanced helical CT for the detection of malignant hepatic tumours: sensitivity based on comparison with intraoperative and pathologic findings. AJR 166:91-95
21. Semelka RC, Worawattanakul S, Kelekis NL et al (1997) Liver lesion detection, characterization and effect on patient management: comparison of single-phase spiral CT and current MR techniques. J Magn Reson Imaging 7(6):1040-1047
22. Kondo H, Kanematsu M, Hoshi H et al (2000) Preoperative detection of malignant hepatic tumors: comparison of combined methods of MR imaging with combined methods of CT. AJR 174:947-954
23. Schmidt J, Strotzer M, Fraunhofer S, Boedeker H, Zirngibl H (2000) Intraoperative ultrasonography versus helical computed tomography and computed tomography with arterioportography in diagnosing colorectal liver metastases: lesion-by-lesion analysis. World J Surg 24:43-48
24. Bluemke DA, Paulson EK, Choti MA, DeSena S, Clavien PA (2000) Detection of hepatic lesions in candidates for surgery: comparison of ferumoxides-enhanced MR imaging and dual-phase helical CT. AJR 175:1653-1658
25. Valls C, Andia E, Sanchez A et al (2001) Hepatic metastases from colorectal cancer: preoperative detection and assessment of resectability with helical CT. Radiology 218:55-60
26. Bartolozzi C, Donati F, Cioni D et al (2004) Detection of colorectal liver metastases: a prospective multicenter trial comparing unenhanced MRI, MnDPDP-enhanced MRI and spiral CT. Eur Radiol 14(1):14-20
27. Rappeport ED, Loft A, Berthelsen AK et al (2007) Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation. Acta Radiol 48(4):369-378
28. Huguet EL, Old S, Praseedom RK, Balan KK, Gibbs P, Jamieson NV (2007) F18-FDG-PET evaluation of patients for resection of colorectal liver metastases. Hepatogastroenterology 54(78):1667-1671
29. Valls C, Lopez E, Guma A et al (1998) Helical CT versus CT arterial portography in the detection of hepatic metastases of colorectal carcinoma. AJR 170:1341-1347
30. Ward J, Naik KS, Guthrie JA, Wilson D, Robinson PJ (1999) Hepatic lesion detection: comparison of MR imaging after the administration of superparamagnetic iron oxide with dual-phase CT by using alternative-free response receiver operating characteristic analysis. Radiology 210:459-466
31. Furuhata T, Okita K, Tsuruma T et al (2003) Efficacy of SPIO-MR imaging in the diagnosis of liver metastases from colorectal carcinomas. Dig Surg 20:321-325
32. 18F-FDG PET/CT in colorectal liver metastasescomparison with CT and liver MRI. Eur J Nucl Med Mol Imaging 35:1323-1329
33. Ogunbiyi OA, Flanagan FL, Dehdashti F et al (1997) Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 4(8):613-620
34. Topal B, Flamen P, Aerts R et al (2001) Clinical value of whole-body emission tomography in potentially curable colorectal liver metastases. Eur J Surg Oncol 27(2):175-179
35. Arulampalam TH, Francis DL, Visvikis D, Taylor I, Ell PJ (2004) FDG-PET for the pre-operative evaluation of colorectal liver metastases. Eur J Surg Oncol 30(3):286-291
36. Gambhir SS, Czernin J, Schwimmer J, Silverman DHS, Coleman RE, Phelps ME (2001) A tabulated summary of the FDG-PET literature. J Nucl Med 42:1S-93S
37. Strauss LG, Clorius JH, Schlag P et al (1989) Recurrence of colorectal tumors: PET evaluation. Radiology 170:329-332
38. Zealley IA, Skehan SJ, Rawlinson J, Coates G, Nahmias C, Somers S (2001) Selection of patients for resection of hepatic metastases: improved detection of extrahepatic disease with FDG-PET. Radiographics 21(Spec No):S55-69
39. Desai DC, Zervos EE, Arnold MW, Burak WE Jr, Mantil J, Martin EW Jr (2003) Positron emission tomography affects surgical management in recurrent colorectal cancer patients. Ann Surg Oncol 10(1):59-64
40. Sheehan JJ, Ridge CA, Ward EVM et al (2007) FDG PET in preoperative assessment of colorectal liver metastases combining evidence-based practice and technology assessment methods to develop departmental imaging protocols: should FDG PET be routinely used in the preoperative assessment of patients with colorectal liver metastases? Acad Radiol 14:389-397
41. Lubezky N, Metser U, Geva R et al (2007) The role and limitations of 18-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. J Gastrointest Surg 11(4):472-478
42. Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA (2004) Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 240(6):1027-1034
43. Joyce DL, Wahl RL, Patel PV, Schulick RD, Gearhart SL, Choti MA (2006) Preoperative positron emission tomography to evaluate potentially resectable hepatic colorectal metastases. Arch Surg 141(12):1220-1226
44. Wiering B, Krabbe PF, Jager GJ, Oyen WJ, Ruers TJ (2005) The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 104(12):2658-2670
45. Ruers TJ, Langenhoff BS, Neeleman N et al (2002) Value of positron emission tomography with [F18] fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol 20:388-395
46. Lai DT, Fulham M, Stephen MS et al (1996) The role of whole-body positron emission tomography with [18F] fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg 131:703-707
47. Beyer T, Townsend D, Brun T et al (2000) A combined PET/CT scanner for clinical oncology. J Nucl Med 41:1369-1379
48. Cohade C, Osman M, Leal J, Wahl RL (2003) Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 44(11):1797-1803
49. Kim JH, Czernin J, Allen-Auerbach MS et al (2005) Comparison between 18F-FDG PET, in-line PET/CT and software fusion for restaging of recurrent colorectal cancer. J Nucl Med 46(4):587-595
50. Wildi SM, Gubler C, Hany T et al (2008) Intraoperative sonography in patients with colorectal cancer and resectable liver metastases on preoperative FDG-PET-CT. J Clin Ultrasound 36(1):20-26
51. Kamel IR, Cohade C, Neyman E, Fishman EK, Wahl RL (2004) Incremental value of CT in PET/CT of patients with colorectal carcinoma. Abdom Imaging 29:663-668
52. Votrubova J, Belohlavek O, Jaruskova M et al (2006) The role of FDG-PET/CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Mol Imaging 33:779-784
53. Vidiri A, Carpanese L, Annibale MD et al (2004) Evaluation of hepatic metastases from colorectal carcinoma with MR-superparamagnetic iron oxide. J Exp Clin Cancer Res 23(1):53-60
54. Hagspiel KD, Neidl KFW, Eichenberger AC, Weder W, Marincek B (1995) Detection of liver metastases: comparison of superparamagnetic iron oxide-enhanced and unenhanced MR imaging at 1.5T with dynamic CT, intraoperative US and percutaneous US. Radiology 196:471-478
55. Ward JA, Guthrie D, Wilson P et al (2003) Colorectal hepatic metastases: detection with SPIO-enhanced breath-hold MR imagingcomparison of optimized sequences. Radiology 228(3):709-718
56. Chezmar JL, Rumancik WM, Megibow AJ, Hulnick DH, Nelson RC, Bernadino ME (1988) Liver and abdominal screening in patients with cancer: CT versus MR imaging. Radiology 168:43-47
57. Barakos JA, Goldberg HI, Brown JJ, Gilbert TJ (1990) Comparison of computed tomography and magnetic resonance imaging in the evaluation of focal hepatic lesions. Gastrointest Radiol 15:93-101
58. Seneterre E, Taourel P, Bouvier Y et al (1996) Detection of hepatic metastases: ferumoxides-enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography. Radiology 200:785-792
59. Petersein J, Spinazzi A, Giovagnoni A et al (2000) Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging-a multicenter phase III clinical study. Radiology 215:727-736
60. Bhattacharjya S, Bhattacharjya T, Baber S, Tibballs JM, Watkinson AF, Davidson BR (2004) Prospective study of contrast-enhanced computed tomography, computed tomography during arterioportography and magnetic resonance imaging for staging colorectal liver metastases for liver resection. Br J Surg 91:1361-1369
61. Whitney WS, Herfkens RJ, Jeffrey RB et al (1993) Dynamic breath-hold multiplanar spoiled gradient-recall MR imaging with gadolinium enhancement for differentiating hepatic hemangiomas from malignancies at 1.5 T. Radiology 189:863-870
62. Semelka RC, Shoenut JP, Ascher SM et al (1994) Solitary hepatic metastasis: comparison of dynamic contrast-enhanced CT and MR imaging with fat-suppressed T2-weighted, breath-hold T1-weighted FLASH and dynamic gadolinium-enhanced FLASH sequences. J Magn Reson Imaging 4:319-323
63. Semelka RC, Martin DR, Balci C, Lance T (2001) Focal liver lesions: comparison of dual-phase CT and multisequence multiplanar MR imaging including dynamic gadolinium enhancement. Magn Reson Imaging 13:397-401
64. Ros PR, Freeny PC, Harms SE et al (1995) Hepatic MR imaging with ferumoxides: a multicentre clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 196:481-488
65. Oudkerk M, Van Den Heuvel AG, Wielopolski PA, Schmitz PIM, Borel Rinkes IHM, Wiggers T (1997) Hepatic lesions: detection with ferumoxide-enhanced T1-weighted MR imaging. Radiology 203:449-456
66. Reimer P, Jahnke N, Feibich M et al (2000) Hepatic lesion detection and characterization: value of non-enhanced MR imaging, superparamagnetic iron oxide-enhanced MR imaging and spiral CTROC analysis. Radiology 217:152-158
67. Arbab AS, Ichikawa T, Sou H et al (2002) Ferumoxides-enhanced double-echo T2-weighted MR imaging in differentiating metastases from nonsolid benign lesions of the liver. Radiology 225:151-158
68. Torres CG, Lundby B, Sterud AT, McGill S, Gordon PB, Bjerknes HS (1997) MnDPDP for MR imaging of the liver: results from the European phase III studies. Acta Radiol 38:631-637
69. Oudkerk M, Torres CG, Song B et al (2002) Characterization of liver lesions with mangafodipir trisodium-enhanced MR imaging: multicenter study comparing MR and dual-phase spiral CT. Radiology 223:517-524
70. Ward J, Robinson PJ, Guthrie JA et al (2005) Liver metastases in candidates for hepatic resection: comparison of helical CT and gadolinium- and SPIO-enhanced MR imaging. Radiology 237:170-180
71. Hamm B, Mahfouz A-E, Taupitz M et al (1997) Liver metastases: improved detection with dynamic gadolinium-enhanced MR imaging? Radiology 202:677-682
72. Bennett GL, Petersein A, Mayo-Smith WW, Hahn PF, Schima W, Saini S (2000) Addition of gadolinium chelates to heavily T2-weighted MR imaging: limited role in differentiating hepatic hemangiomas from metastases. AJR 174:477-485
73. Schima W, Fugger R, Schober E et al (2002) Diagnosis and staging of pancreatic cancer: comparison of mangafodipir-enhanced MRI and contrast-enhanced helical hydro-CT. AJR 179:717-724
74. Mann GN, Mary HF, Lai LL, Wagman LD (2001) Clinical and cost effectiveness of a new hepatocellular MRI contrast agent, mangafodipir trisodium, in the preoperative assessment of liver resectability. Ann Surg Oncol 8:573-579
75. Hamm B, Staks T, Muehler A et al (1995) Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary contrast agent: safety, pharmacokinetics and MR imaging. Radiology 195:785-792
76. Caudana R, Morana G, Pirovano GP et al (1996) Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA)preliminary results of phase II clinical application. Radiology 199:513-520
77. Hammerstingl R, Huppertz A, Breuer J et al (2008) Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol 18:457-467
78. Jenkins LT, Millikan KW, Bines SD, Staren ED, Doolas A (1997) Hepatic resection for metastatic colorectal cancer. Am Surg 63(7):605-610
79. Fuhrman GM, Curley SA, Hohn DC, Roh MS (1995) Improved survival after resection of colorectal liver metastases. Ann Surg Oncol 2(6):537-541
80. Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF (2002) Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 224(3):748-756
81. Akhurst T, Kates TJ, Mazumdar M et al (2005) Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol 23:8713-8716
82. Oi H, Murakami T, Kim T et al (1996) Dynamic MR imaging and early-phase helical CT for detecting small intrahepatic metastases of hepatocellular carcinoma. AJR 166:369-374
83. Peterson MS, Baron RL, Murakami T (1996) Hepatic malignancies: usefulness of acquisition of multiple arterial and portal venous phase images at dynamic gadolinium-enhanced MR imaging. Radiology 201:337-345
84. Yamashita Y, Mitsuzaki K, Yi T et al (1996) Small hepatocellular carcinoma in patients with chronic liver damage: prospective comparison of detection with dynamic MR imaging and helical CT of the whole liver. Radiology 200:79-84
85. Blakeborough A, Ward J, Wilson D et al (1997) Hepatic lesion detection at MR imaging: a comparative study with four sequences. Radiology 203:759-765
86. Hawighorst H, Schoenberg S, Knopp MV et al (1999) Hepatic lesions: morphologic and functional characterization with multiphase breath-hold 3D gadolinium-enhanced MR angiographyinitial results. Radiology 210:89-96
87. Winterer JT, Kotter E, Ghanem N, Langer M (2006) Detection and characterization of benign focal liver lesions with multislice CT. Eur Radiol 16:2427-2443
88. Kim YK, Lee JM, Kim CS, Chung GH, Kim CY, Kim IH (2005) Detection of liver metastases: gadobenate dimeglumine-enhanced three-dimensional dynamic phases and one-hour delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging. Eur Radiol 15:220-228
89. Simon G, Link TM, Wortler K et al (2005) Detection of hepatocellular carcinoma: comparison of Gd-DTPA- and ferumoxides-enhanced MR imaging. Eur Radiol 15:895-903
90. Vogl TJ, Kummel S, Hammerstingl R et al (1996) Liver tumours: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 201:59-67
91. Reimer P, Rummeny E, Shamsi K et al (1996) Phase II Clinical evaluation of Gd-EOB-DTPA: dose, safety aspects and pulse sequence. Radiology 199:177-183
92. Robinson PJ (2002) The early detection of liver metastases. Cancer Imaging 2:113-115
93. Van Beers BE, Lacrosse M, Jamart J et al (1997) Detection and segmental location of malignant hepatic tumors: comparison of ferumoxides-enhanced gradient-echo and T2-weighted spin-echo MR imaging. AJR 168:713-717
94. Muller RD, Vogel K, Neumann K et al (1999) SPIO-MR imaging versus double-phase spiral CT in detecting malignant lesions of the liver. Acta Radiol 40:628-635
95. Poeckler-Schoeniger C, Koepke J, Gueckel F, Sturm J, Georgi M (1999) MRI with superparamagnetic iron oxide: efficacy in the detection and characterization of focal hepatic lesions. Magn Reson Imaging 17:383-392
96. Van Etten B, van der Sijp J, Kruyt R, Oudkerk M, van der Holt B, Wiggers T (2002) Ferumoxide-enhanced magnetic resonance imaging techniques in pre-operative assessment of colorectal liver metastases. Eur J Surg Oncol 28:645-651
97. Kim MJ, Kim JH, Chung JJ, Park MS, Lim JS, Oh YT (2003) Focal hepatic lesions: detection and characterization with combination gadolinium- and superparamagnetic iron oxide-enhanced MR imaging. Radiology 228:719-726
98. Takahama K, Amano Y, Hayashi H, Ishihara M, Kumazaki T (2003) Detection and characterization of focal liver lesions using superparamagnetic iron oxide-enhanced magnetic resonance imaging: comparison between ferumoxides-enhanced T1-weighted imaging and delayed-phase gadolinium-enhanced T1-weighted imaging. Abdom Imaging 28:525-530
99. Vogl TJ, Schwarz W, Blume S et al (2003) Preoperative evaluation of malignant liver tumors: comparison of unenhanced and SPIO (Resovist)-enhanced MR imaging with biphasic CTAP and intraoperative US. Eur Radiol 13:262-272
100. Fretz CJ, Stark DD, Metz CE et al (1990) Detection of hepatic metastases: comparison of contrast-enhanced CT, unenhanced MR imaging and iron-enhanced MR imaging. AJR 155:763-770
101. Scott J, Ward J, Guthrie JA, Wilson D, Robinson PJ (2000) MRI of liver: a comparison of CNR enhancement using high dose and low dose ferumoxide infusion in patients with colorectal liver metastases. Magn Reson Imaging 18:297-303
102. Matsuo M, Kanematsu M, Itoh K et al (2001) Detection of malignant hepatic tumors: comparison of gadolinium- and ferumoxide-enhanced imaging. AJR 177:637-643
103. Kim KW, Kim AY, Kim TK et al (2004) Small (≤2 cm) hepatic lesions in colorectal cancer patients: detection and characterization on mangafodipir trisodium-enhanced MRI. AJR 182:1233-1240